Posted inBiotechnology
Assessing Malaria Surveillance Trends in Jimma, Ethiopia
In an era where global health concerns continue to evolve, the focus on infectious diseases such as malaria remains crucial.…
Posted inBiotechnology
Combined PD-1 Ligands Boost rAAV Gene Expression
In a groundbreaking study featured in Gene Therapy, researchers have made significant advancements in gene delivery techniques by exploring the…
Posted inGenetics
Cause for Progressive Blindness Identified
Retinitis pigmentosa (RP) is a progressive condition of the retina that reduces the vision of affected individuals. Over time, photosensitive…
Posted inGenetics
Bone Marrow Immune Cell Map Boosts Survival, Relapse Prediction in Multiple Myeloma
A map of the immune cell landscape found in the bone marrow of patients with multiple myeloma could shed light…
Posted inGenetics
New Single‑Cell Testing Measures How Effectively Antibiotics Kill Bacteria
Biofilm of antibiotic resistant bacteria. Rod-shaped and spherical bacteria. E. coli, Pseudomonas, Mycobacterium tuberculosis, Klebsiella, Staphylococcus aureus, MRSA. 3D illustration…
Posted inBiotechnology
AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal
AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a Chinese pharma that aims to treat…
Posted inBiotechnology
Comparing Whole Genome Sequencing Methods for Capripox Viruses
Title: Advancements in Whole Genome Sequencing Approaches for Capripox Viruses In the realm of virology, Capripox viruses have garnered increasing…
Posted inBiotechnology
Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug…
Posted inMedical Technology
Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround
Quanterix has a new chief executive and president in Everett Cunningham, but analysts at Leerink see Illumina’s former commercial chief…
Posted inBiotechnology
Baby KJ scientist launches personalized CRISPR therapy startup
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The…